Sort   by:  
 Page size 
ProteomicsComprehensive investigation of (redox-) proteomic changes induced by cana-, dapa-, empagliflozin treatment in cardiac cells
One of the major macrovascular complications that can occur in type 2 diabetes is the development of cardiovascular diseases as for instance heart failure. However, sodium-glucose co-transporter-2 (SGLT-2) inhibitors have shortly after their approval shown to decrease death rates in diabetic patient...
ORGANISM(S): Homo sapiens (Human) 
2026-01-20 | PXD063467 | Pride
Gliflozins Sglt-2 inhibitors Proteomics Ac16 cells Heart failure Oxidative stress Hcm cells Empagliflozin Redox proteomics Canagliflozin Dapagliflozin 
GenomicsEmpagliflozin restores cardiac function in obese-diabetic HFpEF mice butfurther alters gene expression
Empagliflozin restores cardiac function in obese-diabetic HFpEF mice butfurther alters gene expression
PRJNA1207072 | ENA
GenomicsEmpagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells
Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells
PRJNA1019757 | ENA
GenomicsRNA-expression analysis on smooth muscle cells of diabetic donors after empagliflozin treatment
RNA-expression analysis on smooth muscle cells of diabetic donors after empagliflozin treatment
PRJNA783346 | ENA
GenomicsRNA seq analysis of human macrophages after treatment of glimepiride versus empagliflozin.
RNA seq analysis of human macrophages after treatment of glimepiride versus empagliflozin.
PRJNA554789 | ENA
TranscriptomicsEmpagliflozin restores cardiac function in obese-diabetic HFpEF mice butfurther alters gene expression
Effective treatments for heart failure with preserved ejection fraction (HFpEF) are limited. Empagliflozin, a sodium-glucosecotransporter-2 (SGLT2) inhibitor, provides cardiovascular benefits for patients with HFpEF. SGLT2 expression is virtually absent in cardiomyocytes, hence the exact protective ...
ORGANISM(S): Mus musculus 
2026-05-13 | GSE285966 | GEO
TranscriptomicsEmpagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells
SGLT-2 inhibitors, such as empagliflozin, have been shown to reduce the occurrence of cardiovascular events and delay the progression of atherosclerosis. However, its role in atherosclerotic calcification remains unclear. In this research, ApoE-/- mice were fed with western diet and empagliflozin wa...
ORGANISM(S): Rattus norvegicus 
2023-11-22 | GSE243752 | GEO
TranscriptomicsRNA-expression analysis on smooth muscle cells of diabetic donors after empagliflozin treatment
Purpose: We report vascular effects of empagliflozin stimulation. Results: Gene set enrichment analysis of RNA-Seq showed negative regulation of vascular smooth muscle cell proliferation. Gene set overlapped by the vasoactive peptide apelin, being upregulated by empagliflozin treatment.
ORGANISM(S): Homo sapiens 
2021-11-27 | GSE189538 | GEO
TranscriptomicsRNA seq analysis of human macrophages after treatment of glimepiride versus empagliflozin.
Purpose: The goal of this study is to compare NGS-derived macrophage transcriptome profiling (RNA-seq) between diabetic patients treated with glimepiride versus empagliflozin. Methods: Macrophage mRNA profiles of 7 patients treated with either glimepiride or empagliflozin were generated by deep sequ...
ORGANISM(S): Homo sapiens 
2019-07-17 | GSE134329 | GEO
TranscriptomicsEmpagliflozin restores colonic fatty acid metabolism and ameliorates fibrotic signalling despite gut dysbiosis in Western diet-fed mice
Aims Gut dysbiosis and an altered host colonic transcriptomic response are significant contributors to metabolic deterioration with westernization of the diet. Despite the wide usage of SGLT2 inhibitors in patients with type 2 diabetes, chronic kidney disease and/or heart failure, intestinal effects...
ORGANISM(S): Mus musculus 
2026-10-05 | GSE318754 | GEO
Sort   by:  
 Page size